Benchmark raises Halozyme stock price target to $90 on strong results
#Benchmark #Halozyme Therapeutics #Price target #Non‑GAAP earnings #Revenue growth #Royalties #Q4 2025 #Nasdaq #Buy rating #Acquisition write‑offs #2026 guidance
📌 Key Takeaways
- Benchmark raised Halozyme’s price target to $90 from $75, maintaining a Buy rating.
- Halozyme reported Q4 2025 revenue of $451.8 million, a 52% year‑over‑year increase.
- Non‑GAAP earnings rose to $2.18 per share before $2.42 in acquisition write‑offs, resulting in a $0.24 loss per share.
- Revenue growth was mainly from increased royalties on Darzalex SC, Phesgo, and Vyvgart Hytrulo and higher product sales.
- Benchmark’s price target is based on a six‑times estimate of 2026 revenue.
- Halozyme reaffirmed its 2026 revenue and earnings guidance, noting lower Q1 revenue due to royalty calculation timing.
- TD Cowen also raised its target to $96, citing royalty growth as a key driver.
📖 Full Retelling
Benchmark, a financial research firm based in the United States, increased its price target for Halozyme Therapeutics Inc. (NASDAQ: HALO) shares to $90 from $75 on February 19, 2026, following the drugmaker’s fourth‑quarter 2025 financial results. The rating upgrade was driven by a 52% revenue jump to $451.8 million, driven largely by royalty income from Darzalex SC, Phesgo, and Vyvgart Hytrulo, and a non‑GAAP earnings bounce to $2.18 per share before acquisition write‑offs. Despite posting a $0.24 loss per share, the company reaffirmed its 2026 guidance, prompting Benchmark to revise its target based on a six‑times revenue multiple.
🏷️ Themes
Financial analysis, Biopharmaceutical industry, Stock market valuation, Earnings reporting, Investment ratings
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices edge higher; geopolitical tensions outweigh hawkish Fed minutes Hawkish hints in Fed minutes; Walmart to report - what’s moving markets Morgan Stanley identifies best gas stocks amid AI data center boom US ready to begin war on Iran by Saturday - report FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Benchmark raises Halozyme stock price target to $90 on strong results By Investing.com Analyst Ratings Published 02/19/2026, 11:19 AM Benchmark raises Halozyme stock price target to $90 on strong results 0 HALO -2.28% Investing.com - Benchmark raised its price target on Halozyme Therapeutics Inc. (NASDAQ:HALO) shares to $90 from $75 on Wednesday while maintaining a Buy rating following the company’s fourth-quarter results. Halozyme reported revenues of $451.8 million for the fourth quarter of 2025, representing a 52% increase from the same period last year. The company posted a non-GAAP diluted loss per share of $0.24, which included $2.42 per share in acquisition-related write-offs. Before charges, non-GAAP earnings reached $2.18 per share compared to $1.26 in the prior year. Benchmark had estimated revenues of $444.3 million and non-GAAP earnings of $2.20 for the quarter. Revenue growth was driven by increased royalties from prescription growth for Darzalex SC, Phesgo and Vyvgart Hytrulo, along with higher product sales. Halozyme reiterated its revenue and earnings guidance for 2026, noting lower revenues expected in the first quarter due to the timing of royalty rate calculations. Benchmark based its new $90 price target on 6 times estimated revenues for 2026. The shares had reached the firm’s previous price target of $75. In other recent news, Halozyme Therapeutics reported a fourth-quarter loss, surprising investors despite its impressive revenue growth. The company posted an adjusted loss of $0.24 per share, which was a significant miss compared to analyst expectations of a $1.90 profit...
Read full article at source